Mesa Laboratories, Inc. · NASDAQ:MLAB
Mesa Laboratories — Merger or Acquisition (September 2021)
9 slides from Mesa Laboratories's merger presentation, Sep 14, 2021
Slide 1: Mesa Labs Announces Agreement to Acquire Agena Bioscience, Inc
MesaLabs Mesa Labs Announces Agreement to Acquire Agena Bioscience, Inc September 14, 2021 Gary Owens, P!
Slide 2: Safe Harbor Statement
Safe Harbor Statement This presentation contains forward-looking statements within the meaning of the federal securities laws. Investorsare cautioned that statements in this press release which are not strictly historical statements including, without limitation, express or implied statements or gui
Slide 3: Strategic Rationale
Strategic Rationale Attractive Growth Strong Team The Mesa Way ) Unique platform serving the fast-growing clinical genomics market increasing Mesa’s organic growth potential Brings a talented global team with depth transitioning genomics from Discovery to Clinical Opportunity to leverage The Mesa Wa
Slide 4: Agena Bioscience Snapshot
Agena Bioscience Snapshot 100% Non-Clinical Ciel . Capex Hardware $60m 80% June 2021 TTM g Revenue 48 i $ 60% - 5 ee Mid-60’s% #2 08 Gross Profit iS North =F 10% ‘America Hereditary High Single Digit Anticipated Core 0% Revenues Growth Geography Revenue Type Therapeutic Area Channel Global presence,
Slide 5: Agena Bioscience Platform
Agena Bioscience Platform Agena + Plex * Clearseex * Ultraseek Chemistry MassARRAY System Flexible Architecture for LT and IvD P_) Hardware Consumables SpectrocHiP ur Differentiated, proven, flexible platform for targeted Clinical Genomics MesaLabs
Slide 6: Clinical Genomics — Applications
Clinical Genomics — Applications ‘Oncology Pan Cancer Sereening Psychiatrie Emerging (Gastro, UT, ST) ‘Tumor Informed Seresning Oncology Carrier Screening STDs Solid Tumor profiling Pain Newborn / Pediatrie Viral Load Tumor Informed Tx/Rx Guidance Cardiology Deafness Blood Screening “Tumor Informed
Slide 7: Application Example — Hereditary (Cystic Fibrosis)
Application Example — Hereditary (Cystic Fibrosis) Hereditary Genetics Therapies * Cystic Fibrosis (CF) is a hereditary genetic disease that causes persistent lung infections + FDAapproved first DNA test for CF in 2005 + Genetic screening for CF has been recommended for over a decade from ACMG* and
Slide 8: Application — PharmacoGenetics (PGx)
Application — PharmacoGenetics (PGx) : Genomics Disease . . : 0 + PharmacoGenetic tests (PGx) are performed to evaluate a person’s potential response to a drug therapy + Many FDA approved drugs (> 250 FDA) require PGx designations to ensure patient safety, dosing and response to therapy * PGx tests
Slide 9: Transaction Details
Transaction Details High single digit core revenues in the mid-term with strong operating leverage. Longer-term strategic upside in accelerated China IVD and Oncology Growth » Potential Expect high single digit AOI returns by year 5, AO! per share ROIC at . accretive in year 1 Funding ) Cash on hand
Mesa Laboratories — Merger or Acquisition (September 2021) on 6ix